Payment overview · 2025
General Payments
$304.84
15 reported records · 10 companies
Healthcare provider profile · identity verified
David Ismael Cabral, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HICKORY, NC · NPI 1407031420
Verified facts
What the public records show
CMS Open Payments records show David Ismael Cabral, MD received $304.84 in general payments during 2025 across 15 reported records.
Novo Nordisk Inc accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.23 | 22.7% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.84 | 17.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.85 | 15.4% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $25.68 | 8.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.82 | 6.8% | 1 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $20.55 | 6.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.40 | 6.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.32 | 6.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.69 | 5.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.46 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $304.84 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $51.84 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.85 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.58 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.58 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.65 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 178 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
178 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 512 | 155 |
| Levothyroxine Sodium | Levothyroxine Sodium | 358 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 307 | 76 |
| Omeprazole | Omeprazole | 285 | 77 |
| Lisinopril | Lisinopril | 277 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 86 |
| Metformin Hcl | Metformin Hcl | 268 | 83 |
| Losartan Potassium | Losartan Potassium | 244 | 67 |
| Furosemide | Furosemide | 238 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 220 | 37 |
| Gabapentin | Gabapentin | 203 | 58 |
| Alprazolam | Alprazolam | 194 | 35 |
| Meloxicam | Meloxicam | 194 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 53 |
| Lorazepam | Lorazepam | 183 | 35 |
| Ozempic | Semaglutide | 178 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 55 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 169 | 50 |
| Ezetimibe | Ezetimibe | 167 | 50 |
| Pioglitazone Hcl | Pioglitazone Hcl | 159 | 53 |
| Tramadol Hcl | Tramadol Hcl | 159 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 155 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 148 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 147 | 39 |
| Clonazepam | Clonazepam | 144 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 39 |
| Eliquis | Apixaban | 141 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 37 |
| Simvastatin | Simvastatin | 132 | 37 |
| Potassium Chloride | Potassium Chloride | 114 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 32 |
| Trazodone Hcl | Trazodone Hcl | 107 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 28 |
| Montelukast Sodium | Montelukast Sodium | 93 | 32 |
| Alendronate Sodium | Alendronate Sodium | 92 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 21 |
| Azithromycin | Azithromycin | 88 | 73 |
| Celecoxib | Celecoxib | 83 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 17 |
| Carvedilol | Carvedilol | 73 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 18 |
| Glipizide | Glipizide | 66 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 66 | 21 |
| Sertraline Hcl | Sertraline Hcl | 64 | 17 |
| Atenolol | Atenolol | 62 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 16 |
| Pregabalin | Pregabalin | 59 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 11 |
| Fenofibrate | Fenofibrate | 54 | 16 |
| Linzess | Linaclotide | 51 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 15 |
| Allopurinol | Allopurinol | 47 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 13 |
| Ibuprofen | Ibuprofen | 46 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 13 |
| Diazepam | Diazepam | 40 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | 11 |
| Valacyclovir | Valacyclovir Hcl | 35 | 12 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Famotidine | Famotidine | 32 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 17 |
| Jardiance | Empagliflozin | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 13 |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 18 |
| Ramipril | Ramipril | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Prednisone | Prednisone | 18 | 16 |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $304.84 · 15 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, Cologuard Collection Kit, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, JARDIANCE, KEVEYIS, Kerendia, OTEZLA, Ozempic, REPATHA, Rybelsus, TERIPARATIDE, TRELEGY ELLIPTA, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error